Shape the Future of Non-Invasive Cardiovascular Diagnostics
Explore our vision, milestones, and market opportunity. Join us in transforming how heart disease is diagnosed and managed worldwide.
This website contains information intended only for persons professionally dealing with medical devices (e.g. for persons performing medical professions, for persons dealing with the distribution of medical devices). Please confirm that you are a medical device professional to proceed.
Explore our vision, milestones, and market opportunity. Join us in transforming how heart disease is diagnosed and managed worldwide.
cardiac deaths in patients with no prior heart disease history/symptoms
of total disease burden by cause, World, 2021
total deaths globally in 2023
2019 – 703 M, 2050 – 1.5 B
Cardiolens Platform Market Value About Cardiolens® PlatformWe are currently developing an AI-enhanced, non-invasive cardiac diagnostic platform intended to support physicians in assessing patients with suspected coronary artery disease (CAD).
Our solution is in the development phase and is undergoing clinical validation. The platform aims to support decision-making in cardiovascular diagnostics by utilizing advanced computational modeling techniques, including in-silico simulations, AI-driven image analysis, and computational fluid dynamics.
Mission & VisionWe provide our technology for personalized, harmless, and accurate diagnostics to reduce invasive procedures in healthcare.
We believe in innovative medicine that is transformed by AI technology from invasive procedures to patient-friendly, accurate, and safe methods in diagnostics and treatment.
Company founded – The foundation was laid with a bold vision to transform cardiovascular diagnostics through innovation and technology.
Proof of Concept unveiled – Initial concept validated, setting the stage for product development and clinical relevance.
Team and structure development – Organizational build-up begins. Provisional patent application submitted in the US to protect core technology.
Clinical trials and MVP launch – Medical trials initiated. First positive clinical results achieved. Cloud-based MVP validated. Final patent applications filed in both the US and EU.
Strategic growth and expansion – Five-year roadmap introduced. Investor engagement accelerated. First European office opened in the Netherlands to support international expansion.
Advancing clinical validation and commercial readiness – Continued clinical research to strengthen evidence base. Key steps taken to build commercial capabilities and prepare for market entry.
Establishing presence in the Netherlands – Opening of a regional office to support European operations, foster investor relations, and lay the groundwork for long-term commercial growth in the EU market.
Expansion into the UK market – Opening of a local office in the United Kingdom to support clinical partnerships, strengthen regulatory positioning, and accelerate commercial presence across the region.
Access Hemolens Diagnostics® Virtual Data Room
